ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK's new strategy Allergy+ and supports ALK's long-term financial ambitions. Needle-free, nasal delivery of adrenaline has the potential to become an important treatment option in anaphylaxis ALK also gains rights to future indications, including acute urticaria flares (in development) ALK to pay USD 145 million in upfront and additional future milestones and sales royalties neffy ® is the first and only approved needle-free emergency treatment for patients experiencing acute and potentially life-threatening allergic reactions. The European Commission granted EUR neffy ® (the trade name for neffy ® in the EU) market authorisation in the EU in August 2024. Furthermore, neffy ® was approved by the US Food and Drug Administration also in August 2024. S
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term [Yahoo! Finance]Yahoo! Finance
- NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 [Yahoo! Finance]Yahoo! Finance
SPRY
Earnings
- 11/13/24 - Miss
SPRY
Sec Filings
- 11/21/24 - Form 4
- 11/21/24 - Form 4
- 11/15/24 - Form 144
- SPRY's page on the SEC website